Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
Express News | Catalyst Pharmaceuticals Announces Sub-Licensee Dydo Pharma Launched Firdapse® in Japan
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Are Robust Financials Driving The Recent Rally In Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock?
Express News | Catalyst Pharmaceuticals: 2024 Total Net Rev Slightly Exceed Upper End of Latest Guidance
Mangkawat : red day but its still stable
Jaguar8 OP Mangkawat : Nothing big news for me on this one unless it comes with a monetary award
Mangkawat Jaguar8 OP : how about $BioLine Rx (BLRX.US)$ bioline rx. any news ? drop and drop.
Jaguar8 OP Mangkawat : It made an offering days ago
Mangkawat Jaguar8 OP : but price look like on risk to be delist. still below $1 .
View more comments...